Novo Nordisk says Catalent buyout to close soon

Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to close in the coming days.
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod for the $16.5B deal. Read more here.
European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm,
Catalent gains after report sale to Novo Holdings could close soon
Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings could close as soon as Monday. The US Federal Trade Commission doesn't appear to have concerns about the acquisition at this point,
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.
Business Insider17h
Catalent And Novo Holdings Complete All Regulatory Closing Conditions For Merger
(RTTNews) - Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to ...
Novo Holdings’ acquisition of Catalent gains EC approval
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...
BioSpace6d
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...
Indiana Daily Student10d
What Novo’s takeover of Catalent could mean for Bloomington workers
Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...
FiercePharma9d
With green light from European Commission, Novo Holdings' proposed $16.5B Catalent buyout nears close
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Reuters9d
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
BRUSSELS, Dec 6 (Reuters) - Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab after EU ...
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...